/-/media/corpsite/assets/hkstp-logo/hkstp_logo_25_v2_white_0810v2.svg?mw=1980&rev=2a340e7fbf814bbbab9ab7fe854878c7&hash=3E4F85D867EE687322D4B7496A0A452D
directory-icon
Biomedical Technology

i-RNA Asia Limited

Company

i-RNA Asia Limited is a Hong Kong-based subsidiary of Canadian biotechnology company i-RNA Corporation, a spin-off from Western University developing innovative siRNA therapeutics for retinal diseases. Building on over 30 years of pioneering research by Distinguished University Professor Dr Subrata Chakrabarti, the company leverages proprietary siRNA technologies, including novel long non-coding RNA (lncRNA) targets and innovative delivery approaches, to advance first-in-class therapeutic candidates for retinal diseases.With Hong Kong serving as an important base for its research, partnerships, and regional growth, i-RNA Asia supports the continued development of the company's therapeutic pipeline, with lead programs in diabetic retinopathy (DR) and age-related macular degeneration (AMD).

Description

i-RNA Asia Limited is a Hong Kong biotechnology company developing innovative siRNA therapeutics for retinal diseases by leveraging proprietary siRNA technologies targeting long non-coding RNAs (lncRNAs).

Our Beliefs

At i-RNA Asia, we envision a better world seen by everyone. Our mission is to develop innovative siRNA therapeutics that improve outcomes for patients with retinal diseases by enhancing treatment effectiveness, improving patient compliance, and reducing the global burden of vision loss through scientific innovation and strategic collaboration.

Technology

Our approach targets HOTAIR, a long non-coding RNA (lncRNA) that regulates disease-driving pathways, including angiogenesis, inflammation, oxidative stress, and downstream mediators such as VEGF, enabling broader disease-modifying potential beyond current standards of care.Our modified siRNA molecules have demonstrated robust efficacy in preclinical models, including a lead candidate designed for topical eye drop delivery as a non-invasive, patient-friendly alternative to intravitreal anti-VEGF injections, with the potential to improve treatment accessibility and patient compliance.Our pipeline includes preclinical therapeutic candidates for diabetic retinopathy (DR), with ongoing expansion into age-related macular degeneration (AMD) and additional retinal diseases through continued translational research and product development.

Explore other companies

HKG Epitherapeutics Limited455394ac-1ade-e611-80dd-0050569a37d6_CompanyLogo_150724
Biomedical Technology
HKG Epitherapeutics Limited
directory-icon
Biomedical Technology
Acaderma Asia Limited
Applied Technology Group Limitedcade7e94-2178-e711-8102-0050569afff2_CompanyLogo_17072026
Biomedical Technology
Applied Technology Group Limited
MAXINOVEL HONGKONG LIMITEDd08b8531-a60e-f011-998a-002248579afd_CompanyLogo_07092026
Biomedical Technology
MAXINOVEL HONGKONG LIMITED
Hong Kong Science & Technology Parks Corporation - Company Directory - i-RNA Asia Limited
Company Directory